Van Andel Research Institute is ranked among medical research organizations in Grand Rapids, MI, with an America's Best Score of 71 out of 100, based on its 2025 Form 990.
Van Andel Research Institute is a 501(c)(3) organization, classified under Medical Research (NTEE H300). Contributions are tax-deductible.
333 Bostwick Ave Ne, Grand Rapids, MI 49503-2518
Among the 4 scored medical research organizations in Grand Rapids, Van Andel Research Institute holds 16.5 months of operating reserves (peer median 14 months), runs a typical yearly surplus of 13.3% (peers: surplus of 12.7%), and has grown spending 3.8% a year (peers: grown spending 2.8% a year).
In fiscal year 2025 it reported $127,211,515 in revenue and $126,984,813 in expenses, with contributions making up 88.3% of revenue.
Medical research organization Van Andel Research Institute is an independent biomedical research organization committed to improving the health and enhancing the lives of current and future generations.
Largest programs · fiscal year 2025
Department of epigeneticsschedule o provides further information regarding this program's accomplishments.$16,838,090 spent · 20.6% of program spending
Department of neurodegenerative scienceschedule o provides further information regarding this program's accomplishments.$9,837,343 spent · 12.0% of program spending
Department of metabolism and nutritional programmingsee schedule o for further information about this program's accomplishments.$8,470,515 spent · 10.3% of program spending
Line 4d - other program services department of cell biology as of November 2025, the department of cell biology, led by interim chair dr. Yvonne fondufe-mittendorf, comprised seven labs that pursue fundamental research to understand how cells grow, communicate, survive, assemble into tissues and organs, respond to the environment, and change with age. This transformative work aims to yield new dia… Read more
Line 4d - other program services department of cell biology as of November 2025, the department of cell biology, led by interim chair dr. Yvonne fondufe-mittendorf, comprised seven labs that pursue fundamental research to understand how cells grow, communicate, survive, assemble into tissues and organs, respond to the environment, and change with age. This transformative work aims to yield new diagnostic and treatment strategies to improve the quality of life for people with cancer, bone diseases, and rare disorders. One faculty member holds an appointment as director of the institute's core technologies and services. Dr. Fondufe-mittendorf holds a primary appointment in the department of epigenetics. In this fiscal year, researchers and trainees within the department earned new awards from the national institutes of health and the company of biologists. A subaward with a prime sponsor of the national institute of general medical sciences of the national institutes of health was received from z biotech. Department of structural biology as of November 2025, the department of structural biology, chaired by dr. Huilin li, comprised six laboratories that harness the power of cryo-electron microscopy (cryo-em) and other techniques to visualize molecules, complexes, and structures that serve as the foundation for health and disease. These molecules may serve as drug targets for cancer, neurological disorders, metabolic diseases, infectious diseases, and more. Department scientists have interests in dna replication, cellular signaling, rna biology, neurodegeneration, immunology, and epigenetics. In this fiscal year, researchers within the department earned new awards from the national institutes of health and the alfred p. Sloan foundation. A subaward with the prime sponsor of the national cancer institute of the national institutes of health was received from Oregon health & science university. A subaward with the prime sponsor of the national institute of allergy and infectious diseases was received from cornell university. Clinical collaborations the van andel institute-stand up to cancer epigenetics dream team, led by dr. Peter a. Jones and dr. Stephen baylin in 2025, fosters collaboration toward development of new combination therapies for cancer by moving these promising therapies into clinical trials. The team focuses on epigenetic mechanisms in cells, which help control whether genes are switched "on or "off" without changing the dna sequence itself. The international linked clinical trials program identifies potential new therapies that may slow or stop parkinson's progression from medications developed or approved to treat other conditions. The program is spearheaded by cure parkinson's in collaboration with the institute. It aims to reduce the time it takes for a potential treatment to move from the lab into clinical trials and, ultimately, to implementation in the clinic. Dr. Darren moore represents vai on the ilct committee.
$46,720,171 spent · 57.1% of program spending
Where each dollar went · fiscal year 2025
Of every dollar it spent, 64¢ went to programs, 34¢ to management and 2¢ to fundraising.
Programs $81,866,119
Management $43,149,959
Fundraising $1,968,735
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
64%
Below
Compared with Grand Rapids peers
Measure
This organization
Peer median
Operating reserves
16.5 mo
14.0 mo
Typical margin
+13.3%
+12.7%
Spending growth
+3.8% / yr
+2.8% / yr
Debt load
9.8%
12.4%
Peers: the 4 Grand Rapids medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$127,211,515Fiscal year 2025
Expenses$126,984,813Fiscal year 2025
Total assets$193,687,515Fiscal year 2025
Total liabilities$19,047,346Fiscal year 2025
Fiscal year ending November2025
Revenue$127,211,515
Expenses$126,984,813
Net income$226,702
Net assets$174,640,169
Notable sources of revenue
Percent of total revenue
Contributions
$112,326,731
88.3%
Program services
$1,042,225
0.8%
Investment income
$42,293
0.0%
Other (net)
$13,800,266
10.8%
Assets / debt
Total assets
$193,687,515
Total liabilities
$19,047,346
Net assets
$174,640,169
Compensation
Not in our extract for this year.
Fiscal year ending November2024
Revenue$112,738,485
Expenses$118,913,786
Net income−$6,175,301
Net assets$174,319,019
Notable sources of revenue
Percent of total revenue
Contributions
$99,075,223
87.9%
Program services
$1,311,102
1.2%
Investment income
−$339,084
−0.3%
Other (net)
$12,691,244
11.3%
Assets / debt
Total assets
$190,464,759
Total liabilities
$16,145,740
Net assets
$174,319,019
Compensation
Not in our extract for this year.
Fiscal year ending November2023
Revenue$340,011,886
Expenses$112,044,445
Net income$227,967,441
Net assets$180,371,936
Notable sources of revenue
Percent of total revenue
Contributions
$327,656,765
96.4%
Program services
$882,195
0.3%
Investment income
$99,948
0.0%
Other (net)
$11,372,978
3.3%
Assets / debt
Total assets
$197,193,153
Total liabilities
$16,821,217
Net assets
$180,371,936
Compensation
Not in our extract for this year.
Fiscal year ending November2022
Revenue$143,778,282
Expenses$113,718,338
Net income$30,059,944
Net assets−$44,512,015
Notable sources of revenue
Percent of total revenue
Contributions
$129,397,836
90.0%
Program services
$1,224,115
0.9%
Investment income
$2,807,932
2.0%
Other (net)
$10,348,399
7.2%
Assets / debt
Total assets
$219,998,295
Total liabilities
$264,510,310
Net assets
−$44,512,015
Compensation
Officers and key employees
$3,744,359
Share of expenses
3.3%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?